A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis.

  • Burgell, Rebecca (Primary Chief Investigator (PCI))
  • Hogg, Julie (Project Manager)

Project: Research

StatusActive
Effective start/end date9/09/1931/12/24

Keywords

  • Gastroenterology
  • Diabetic Gastroparesis
  • Clinical trial